Backgrounds:
@EN Gram-positive cocci have been an increasing cause of nosocomial infections in recent years. Treatment of these infections is often difficult, particularly infections by methicillin-resistant staphylococcus aureus (MRSA). Teicoplanin, a new
glycopeptide antibiotic, has been reported to have an excellent in vitro and in vivo effect against various gram-positive infections. To evaluate the clinical efficacy of teicoplanin in the treatment of patients with gram-positive bacterial
infection
and to compare the in vitro susceptibility of teicoplanin with other antimicrobials, we performed a prospective open trial of teicoplanin.
@ES Methods:
@EN Twenty patients with infections by gram-positive organism were enrolled. The patients were received 400mg of teicoplanin followed by 200mg from next day as maintenance dose. During the follow-up period, clinical features and laboratory
parameters
were checked to evaluate clinical efficacy and appropriate cultures were followed to determine the microbiologic efficacy. the adverse effects of teicoplanin were also observed.
@ES Results:
@EN The enrolled patients were 16 males and 4 females, whose mean age was 51 *13 years. The categories of infections were bacteremia (5), skin and soft tissue infection (4), empyema (3), UTI (2), pneumonia (1), catheter associated infection (1)
and
infective endocarditis (1). The etiologic organisms isolated were MRSA (9), coagulase-negative Staphlyococcus (5), S. viridans (2), group D streptococous (2), S. pneumoniae (1), and E. faecalis (1). All 20 patients treated with teicoplanin showed
clinical cure (13/2) or clinical improvement (7/20), whereas 90% of isolated organisms were eradicated after teicoplanin therapy. The adverse effect of teicoplanin was minimal.
@ES Conclusion:
@EN Teicoplanin is safe and effective is the therapy many different infections caused by gram-positive oragnisms.
|